ClinicalTrials.gg
RecruitingNCT07654946Updated Aug 26, 2026

Near-Infrared Spectroscopy, Acute Taurine Supplementation, and Isolated Muscular Endurance and Fatigue Resistance in Young Healthy Adults

An interventional study of Acute Taurine Supplementation and Acute Placebo Supplementation in Local Muscular Endurance and Fatigue, NIRS Skeletal Muscle Mitochondrial Capacity and Acute Taurine Supplementation, sponsored by Louisiana State University and A&M College. Recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Louisiana State University and A&M College · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The goal of this clinical trial is to determine the association between near-infrared spectroscopy (NIRS)-derived mitochondrial oxidative phosphorylation (OXPHOS) capacity of the vastus lateralis muscles, and both local muscular endurance capacity and local muscular fatigability of the thigh muscles in young adults. Additionally, this trial aims to determine the effect of acute taurine supplementation on local muscular endurance capacity and local muscular fatigability when compared to a placebo condition. The main questions it aims to answer are:

  1. Will there be a positive correlation between NIRS rate constant (a marker of mitochondrial function) and local muscular endurance capacity, along with a negative correlation between NIRS rate constant and local muscular fatigability?
  2. Will acute taurine supplementation lead to improvements in local muscular endurance capacity and local muscular fatigability when compared to a placebo condition?

Participants will:

  1. Complete a NIRS assessment to non-invasively assess the mitochondrial capacity of both vastus lateralis muscles
  2. Complete two acute supplementation assessment visits (separated by 7-10 days) which involve small blood collections before and after taurine or placebo supplementation
  3. Perform a single-leg extension time-to-exhaustion test to measure local muscular endurance capacity on one leg, along with a repeated maximal voluntary isometric contraction fatigue index test to measure local muscular fatigability on the opposite leg, during each acute supplementation assessment visit.
Read the detailed description

Participants will be recruited from the Louisiana State University campus and the Greater Baton Rouge area. Interested and potentially eligible participants will be identified based on the responses provided to questions on a prescreen assessment survey completed electronically via RedCap. These individuals will then be scheduled for the in-person Screening and Familiarization Visit which will include: a review of the informed consent form; a review of the inclusion/exclusion criteria; a self-report medical history and medication inventory; the collection of demographic information; an assessment of height and weight; an assessment of body composition via bioelectrical impedance analysis; an assessment of resting blood pressure and heart rate; the completion of the Physical Activity Readiness Questionnaire for Everyone (PARQ+) and the Global Physical Activity Questionnaire (GPAQ); an ultrasound assessment to determine adipose tissue thickness at the NIRS assessment sites; and familiarization with primary study assessments. If eligible according to the Screening and Familiarization Visit, participants will complete the NIRS Assessment Visit. Following an overnight fast (≥ 12 hours), with ≥ 24 hours since most recent exercise participation, a NIRS occlusion-based recovery kinetics approach will be used to non-invasively assess the mitochondrial OXPHOS capacity of the vastus lateralis muscle of each leg. On the day prior to this visit, participants will be asked to complete a 24-hour food log. Participants will then be asked to repeat this reported 24-hour food consumption on the day prior to each of the two remaining study assessment visits. Acute Supplementation Assessment Visit 1 will be completed following an overnight fast (≥ 12 hours), with ≥ 72 hours since most recent exercise participation and ≥ 48 hours following the NIRS Assessment Visit. During Acute Supplementation Assessment Visit 1, a baseline blood sample (10 ml) will be collected upon participants' arrival. Participants will then ingest either a taurine or placebo supplement depending on a randomized supplementation order. Next, participants will wait for 60 minutes following supplement ingestion before having another blood sample (10 ml) collected. Then participants will complete the submaximal, single-leg extension (SLE) isotonic contraction time-to-exhaustion (TTE) test on a randomly determined leg, followed by the 4-minute repeated, single-leg maximal voluntary isometric contraction (MVIC) fatigue index test on the contralateral leg. 7-10 days after Acute Supplementation Assessment Visit 1, following a ≥ 12 hour overnight fast and ≥ 72 hours since most recent exercise participation, participants will complete Acute Supplementation Assessment Visit 2. During this visit, all visit procedures will be conducted identically relative to Acute Supplementation Assessment Visit 1, but participants will consume the alternate supplement according to a randomized supplementation order. The 7-10 days between acute supplementation assessment visits will serve as a standard washout period. An unblinded member of the study team will be responsible for randomizing the supplementation order and preparing the supplements for all participant visits. This unblinded study team member will not be involved in any other aspects of data collection, data processing, or data analysis. All study visits will be conducted in the LSU Exercise Physiology Laboratory.

METHODS

  1. Blood Sample Collections. 10 ml of blood will be collected from an antecubital vein both before and 60 minutes after supplement ingestion during each of the two acute supplementation assessment visits. The whole blood will be processed to plasma, frozen at -80⁰ C and subsequently used to assess plasma taurine levels. This will allow the researchers to directly account for plasma taurine levels in response to acute supplement ingestion.
  2. NIRS Assessment to Measure Muscle Mitochondrial OXPHOS. A portable NIRS sensor (Train.Red Plus) will be placed on the vastus lateralis muscle at \~ 30-40% of the distance from the lateral epicondyle to the greater trochanter of the femur of each leg. An Easi-Fit Tourniquet Cuff specifically adapted to work with the Hokanson Rapid Cuff Inflation System will be placed on the upper thigh. After a 5-min rest period, an ischemic calibration procedure will be performed to account for individual differences in adipose tissue thickness. Following a brief recovery (3-5 minutes), the mitochondrial OXPHOS capacity will be measured using a modified mito-6 protocol. In brief, after 2 minutes of cycle ergometry, a series of 8 arterial occlusions will be used to measure the recovery rate of muscle oxygen consumption (mVO2) in a semi-recumbent position. The first 4 arterial occlusions will be 3-5 seconds "on," and 3-5 seconds "off," and the last 4 arterial occlusions will be 5-7 seconds "on" and 5 seconds "off." After a brief rest, the modified mito-6 protocol will be repeated 3 additional times. Performing the modified mito-6 protocol four total times will increase the reliability of the measurement while also affording the exclusion of outlier bouts. Following the last modified mito-6 bout, the participants will rest quietly for 5-10 minutes before one to two final 30-40 second arterial occlusions. These occlusions provide resting mvo2 slopes against which the mito-6 slopes can be compared during analysis. Vastus lateralis stimulation will be achieved using cycle ergometry at approximately 1 watt per kilogram body weight, which may be adjusted slightly up or down based on participant fitness. The goal is to achieve moderate intensity muscle contractions that optimally stimulate the vastus lateralis prior to arterial occlusions. This test procedure will be performed on the vastus lateralis of each leg, preferably simultaneously. The post-exercise mVO2 data will be fitted with a mono-exponential curve to determine the rate constant (k). This data analysis will be conducted in IRXstudio. For each leg, the k-values from the four modified mito-6 bouts will be used to calculate a median. All k-values that are greater than 30% different from this median will be excluded as outliers. All k-values not deemed outliers will be averaged, and these averaged k-values will be the main outcome variables derived from the NIRS assessment. Immediately following the NIRS assessment, adipose tissue thickness and muscular characteristics will be measured using B-mode ultrasound (LOGICe, GE) at the locations of the NIRS sensors. Ultrasound images will be taken in the transverse plane of the vastus lateralis muscles with frequency at 10 MHz, gain at 45%, and depth at 6 cm. These adipose tissue and muscle measures will provide valuable context to the NIRS assessment and may serve as covariates in subsequent analyses.
  3. Submaximal Single-Leg Extension Isotonic Contraction Time-to-Exhaustion Test. A multimodal dynamometer (Humac NORM) will be used to perform this assessment on the quadriceps muscles/knee extensors. First, maximal voluntary isometric contraction (MVIC) will be recorded as the highest torque produced during three attempts in which MVIC is held for five consecutive seconds followed by 30 seconds of rest. Following the establishment of MVIC, there will be a five-minute rest period to allow full recovery prior to initiating the TTE test. For the TTE test, the torque for the isotonic contractions will be set to 20% of MVIC. This low relative load requires low muscle force production and thus will allow isotonic contractions to be sustained for an extended duration (≥ 2 minutes) to test muscular endurance capacity. All isotonic contractions will be performed at 60⁰ range of motion (ROM) (100-160⁰, with 180⁰ indicating a straight leg). Participants will perform one isotonic contraction every two seconds to the cadence of a metronome. A timer will be started at initiation of the TTE test, and participants will continue performing isotonic contractions until either of the following criteria are met: a) the participant stops due to volitional exhaustion; b) the participant cannot maintain the pace of the metronome for ≥ 5 seconds; or c) the participant cannot perform the full ROM for > 2 consecutive attempts. The time in seconds, from the initiation of the first isotonic contraction until any criterion for stopping is met, will be recorded as the TTE and serve as the main outcome variable from this test. A Train.Red NIRS probe and surface EMG probes will be placed on the vastus lateralis muscle to assess muscle oxygen saturation and excitation during the test. The TTE test will be performed first during both acute supplementation assessment visits. The leg on which the TTE test will be performed will be randomly determined for each participant and kept consistent for both acute supplementation assessment visits. This approach will allow the contralateral leg to be designated for the four-minute repeated, single-leg MVIC fatigue index test. The two tests will be performed on separate legs to prevent the risk of fatigue from one test influencing the other test. Randomizing which leg performs the TTE test will prevent systematic bias (e.g., always choosing the dominant leg).
  4. Four-Minute Repeated, Single-Leg Maximal Voluntary Isometric Contraction Fatigue Index Test. A multimodal dynamometer (Humac NORM) will be used to perform this assessment on the quadriceps muscles/knee extensors. Participants will be set up on the device with the knee fixed at a 60° angle relative to full knee extension ROM. Participants will perform 5-second MVICs interspersed by 5-second rest intervals for four consecutive minutes (for a total of 24 repeated MVICs). The measured MVIC torques will be used to calculate fatigue index as the main outcome variable from this test. To calculate fatigue index, the investigators will first take the highest torque achieved from the first three MVICs (i.e., kicks 1-3) and the highest torque achieved from the final three MVICs (i.e., kicks 22-24), then use the following equation:

    ((Peak torque from first 3 MVICs - Peak torque from final 3 MVICs)/(Peak torque from first 3 MVICs)) x 100. A Train.Red NIRS probe and surface EMG probes will be placed on the vastus lateralis to assess muscle oxygen saturation and excitation during the test.

  5. Statistical Analyses. The participant characteristics will be summarized using mean and standard deviation for continuous variables and frequencies/percentages for categorical data. Correlation analyses will be used to determine the association between NIRS rate constant (k) and time-to-exhaustion in the placebo condition, and the association between NIRS k and fatigue index in the placebo condition. Paired t-tests will be used to assess the within-participant differences between time-to-exhaustion and fatigue index in the taurine and placebo conditions. A power analysis was conducted using G*Power for a paired t-test (two-tailed) with an assumed moderate effect of 0.50 for time-to-exhaustion performance with acute taurine supplementation, alpha of 0.05, and power of 0.80. The effect size was established by considering previous findings in the literature but taking a more conservative approach. The analysis indicated a required sample size of at least 34 participants.
02

Conditions studied

  • Local Muscular Endurance and Fatigue
  • NIRS Skeletal Muscle Mitochondrial Capacity
  • Acute Taurine Supplementation

Browse trials for

Keywords

  • NIRS
  • Near-Infrared Spectroscopy
  • Muscle Fatigue
  • Muscular Endurance
  • Skeletal Muscle
  • Mitochondrial Function
  • Taurine Supplementation
  • Exercise Performance
03

In context

Fatigue

2,229 studies on the registry are indexed under Fatigue; 426 are open to participants now.

This study's planned enrollment of 34 is below the median of 54 across 1,757 interventional studies indexed under Fatigue.

Browse Fatigue studies →

Lead sponsor

Louisiana State University and A&M College is the lead sponsor of 13 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable and willing to give written
  • Capable of understanding inclusion and exclusion criteria
  • No medical condition that would limit participation in supervised exercise
  • No current prescription medications known to impact mitochondrial function
  • Sedentary or recreationally active (self-report average MVPA \< 300 mins/week)
  • Willing to allow researchers to use data for research purposes

Exclusion criteria

Exclusion Criteria:

  • Self-report history of diabetes mellitus
  • Self-report history of cardiovascular, peripheral vascular, cerebral vascular, pulmonary, or renal disease
  • Self-report history of uncontrolled hypertension (resting systolic blood pressure > 180 mmHg or diastolic blood pressure > 100 mmHg)
  • Self-report history of blood clotting disorders
  • Self-report history of sickle cell trait
  • Self-report history of myopathy leading to muscle loss, weakness, severe cramps, or myalgia
  • Self-report history of musculoskeletal disorders
  • Self-report history of lower limb musculoskeletal injuries that may cause significant differences in the functional capacities of the right and left legs
  • Self-report history of neurological disorders
  • Active tobacco, E-cigarette, or nicotine use
  • Recent (within previous 2 weeks) consumption of energy drinks or supplements containing ≥ 1 gram of taurine on > 2 days/week
  • Actively taking medications to treat blood-clotting disorders
  • Any condition that, in the judgement of the Principal Investigator, may interfere with study participation and adherence to the protocol
  • Participants may be excluded if measured adipose tissue thickness is > 2.0 cm at the site of NIRS assessment or if the accessor is unable to obtain high-quality NIRS signals
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Acute Taurine Supplementation

    Participants will ingest six taurine capsules (6 grams of taurine)

    Dietary Supplement: Acute Taurine Supplementation

  • Placebo comparator
    Acute Placebo Supplementation

    Participants will ingest six placebo capsules (1.2 grams of microcrystalline cellulose)

    Dietary Supplement: Acute Placebo Supplementation

Interventions

  • Dietary supplementAcute Taurine Supplementation

    Participants will ingest six taurine capsules (6 grams of taurine) following a baseline blood collection to determine baseline plasma taurine levels. 60 minutes following ingestion, there will be an additional blood collection to determine post-supplementation plasma taurine levels. Participants will then perform exercise assessments. The order of taurine supplementation relative to placebo supplementation will be randomized in a double-blind crossover with 7-10 days separating each condition.

  • Dietary supplementAcute Placebo Supplementation

    Participants will ingest six placebo capsules (1.2 grams of microcrystalline cellulose) following a baseline blood collection to determine baseline plasma taurine levels. 60 minutes following ingestion, there will be an additional blood collection to determine post-supplementation plasma taurine levels. Participants will then perform exercise assessments. The order of placebo supplementation relative to taurine supplementation will be randomized in a double-blind crossover with 7-10 days separating each condition.

06

What researchers measure

Primary outcomes

  1. Single Leg Extension Time-to-Exhaustion

    Within-participant comparison of single-leg extension time-to-exhaustion (a measure of local quadriceps muscular endurance capacity) when comparing the acute taurine supplementation and acute placebo supplementation conditions

    Time frame: From Acute Supplementation Assessment Visit 1 to Acute Supplementation Assessment Visit 2, 7-10 days

  2. Single-Leg Muscular Fatigue Index

    Within-participant comparison of fatigue index during 24 repeated maximal voluntary isometric contractions (a marker of local quadriceps muscular fatigability) when comparing the acute taurine supplementation and acute placebo supplementation conditions

    Time frame: From Acute Supplementation Assessment Visit 1 to Acute Supplementation Assessment Visit 2, 7-10 days

  3. Correlation Between Vastus Lateralis NIRS Rate Constant and Single-Leg Extension Time-to-Exhaustion

    The correlation between the rate constant of the vastus lateralis derived from the NIRS occlusion-based recovery kinetics assessment (a marker of mitochondrial OXPHOS capacity) and single-leg extension time-to-exhaustion (a maker of local quadriceps muscular endurance capacity).

    Time frame: From the NIRS Assessment Visit to Acute Supplementation Assessment Visit 2, approximately 2-3 weeks

  4. Correlation Between Vastus Lateralis NIRS Rate Constant and Single-Leg Muscular Fatigue Index

    The correlation between the rate constant of the vastus lateralis derived from the NIRS occlusion-based recovery kinetics assessment (a marker of mitochondrial OXPHOS capacity) and single-leg muscular fatigue index (a maker of local quadriceps muscular fatigability).

    Time frame: From the NIRS Assessment Visit to Acute Supplementation Assessment Visit 2, approximately 2-3 weeks

07

Study locations

1 of 1 sites recruiting
  • Huey P. Long Fieldhouse Exercise Physiology Laboratory
    Baton Rouge, Louisiana 70802, United States
    Recruiting
    • Efthymios Papadopoulos, PhD · Contactepap@lsu.edu · 225-578-0938
08

References and documents

Publications

  • Davis BH, Spielmann G, Johannsen NM, Fairchild V, Allerton TD, Irving BA. Effect of training status on muscle excitation and neuromuscular fatigue with resistance exercise with and without blood flow restriction in young men. Physiol Rep. 2025 Mar;13(6):e70274. doi: 10.14814/phy2.70274. PubMed 40110914 ↗
  • Tripp TR, McDougall RM, Frankish BP, Wiley JP, Lun V, MacInnis MJ. Contraction intensity affects NIRS-derived skeletal muscle oxidative capacity but not its relationships to mitochondrial protein content or aerobic fitness. J Appl Physiol (1985). 2024 Feb 1;136(2):298-312. doi: 10.1152/japplphysiol.00342.2023. Epub 2023 Dec 7. PubMed 38059287 ↗
  • Sumner MD, Beard S, Pryor EK, Das I, McCully KK. Near Infrared Spectroscopy Measurements of Mitochondrial Capacity Using Partial Recovery Curves. Front Physiol. 2020 Feb 14;11:111. doi: 10.3389/fphys.2020.00111. eCollection 2020. PubMed 32116804 ↗
  • Hanna R, Gosalia J, Demalis A, Hobson Z, McCully KK, Irving BA, Mookerjee S, Vairo GL, Proctor DN. Bilateral NIRS measurements of muscle mitochondrial capacity: Feasibility and repeatability. Physiol Rep. 2021 Apr;9(8):e14826. doi: 10.14814/phy2.14826. PubMed 33945230 ↗
  • Ryan TE, Brizendine JT, McCully KK. A comparison of exercise type and intensity on the noninvasive assessment of skeletal muscle mitochondrial function using near-infrared spectroscopy. J Appl Physiol (1985). 2013 Jan 15;114(2):230-7. doi: 10.1152/japplphysiol.01043.2012. Epub 2012 Nov 15. PubMed 23154991 ↗
  • Ryan TE, Erickson ML, Brizendine JT, Young HJ, McCully KK. Noninvasive evaluation of skeletal muscle mitochondrial capacity with near-infrared spectroscopy: correcting for blood volume changes. J Appl Physiol (1985). 2012 Jul;113(2):175-83. doi: 10.1152/japplphysiol.00319.2012. Epub 2012 May 10. PubMed 22582211 ↗
  • Waldron M, Patterson SD, Tallent J, Jeffries O. The Effects of an Oral Taurine Dose and Supplementation Period on Endurance Exercise Performance in Humans: A Meta-Analysis. Sports Med. 2018 May;48(5):1247-1253. doi: 10.1007/s40279-018-0896-2. PubMed 29546641 ↗
  • De Luca A, Pierno S, Camerino DC. Taurine: the appeal of a safe amino acid for skeletal muscle disorders. J Transl Med. 2015 Jul 25;13:243. doi: 10.1186/s12967-015-0610-1. PubMed 26208967 ↗

Individual participant data

Plan to share: Undecided — The investigators have not yet decided on the individual participant data sharing plan. The investigators will determine at a later stage whether data will be shared and the nature of the data sharing.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07654946
Lead sponsor
Louisiana State University and A&M College
Responsible party
Efthymios Papadopoulos (Assistant Professor, Louisiana State University and A&M College) — Principal investigator
First posted
Jun 17, 2026
Start date
Jul 15, 2026
Primary completion
Jan 15, 2027 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Aug 26, 2026

Study contacts

Efthymios Papadopoulos, PhD
Contact
epap@lsu.edu
225-578-0938
Carlante Emerson, MS
Contact
cemers2@lsu.edu
225-733-4693
Alex Cohen, PhD
study chair · Louisiana State University Health Sciences Center in New Orleans

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion